Annual Review of Pharmacology and Toxicology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Oral Anticoagulants Beyond Warfarin
Annu Rev Pharmacol Toxicol. 2023 Sep 27. doi: 10.1146/annurev-pharmtox-032823-122811. Online ahead of print.ABSTRACTDirect oral anticoagulants (DOACs) have largely replaced vitamin K antagonists, mostly warfarin, for the main indications for oral anticoagulation, prevention and treatment of venous thromboembolism, and prevention of embolic stroke in atrial fibrillation. While DOACs offer practical, fixed-dose anticoagulation in many patients, specific restrictions or contraindications may apply. DOACs are not sufficiently effective in high-thrombotic risk conditions such as antiphospholipid syndrome and mechanical heart va...
Source: Annual Review of Pharmacology and Toxicology - September 27, 2023 Category: Drugs & Pharmacology Authors: Renske H Olie Kristien Winckers Bianca Rocca Hugo Ten Cate Source Type: research

Mass Spectrometry-Based Proteogenomics: New Therapeutic Opportunities for Precision Medicine
Annu Rev Pharmacol Toxicol. 2023 Sep 22. doi: 10.1146/annurev-pharmtox-022723-113921. Online ahead of print.ABSTRACTProteogenomics refers to the integration of comprehensive genomic, transcriptomic, and proteomic measurements from the same samples with the goal of fully understanding the regulatory processes converting genotypes to phenotypes, often with an emphasis on gaining a deeper understanding of disease processes. Although specific genetic mutations have long been known to drive the development of multiple cancers, gene mutations alone do not always predict prognosis or response to targeted therapy. The benefit of p...
Source: Annual Review of Pharmacology and Toxicology - September 22, 2023 Category: Drugs & Pharmacology Authors: Sunil K Joshi Paul Piehowski Tao Liu Sara J C Gosline Jason E McDermott Brian J Druker Elie Traer Jeffrey W Tyner Anupriya Agarwal Cristina E Tognon Karin D Rodland Source Type: research

Artificial Intelligence for Drug Discovery: Are We There Yet?
Annu Rev Pharmacol Toxicol. 2023 Sep 22. doi: 10.1146/annurev-pharmtox-040323-040828. Online ahead of print.ABSTRACTDrug discovery is adapting to novel technologies such as data science, informatics, and artificial intelligence (AI) to accelerate effective treatment development while reducing costs and animal experiments. AI is transforming drug discovery, as indicated by increasing interest from investors, industrial and academic scientists, and legislators. Successful drug discovery requires optimizing properties related to pharmacodynamics, pharmacokinetics, and clinical outcomes. This review discusses the use of AI in ...
Source: Annual Review of Pharmacology and Toxicology - September 22, 2023 Category: Drugs & Pharmacology Authors: Catrin Hasselgren Tudor I Oprea Source Type: research